RxDoctor Payments Data

Mark Iacobucci, MD

Ophthalmology · Portsmouth, VANPI 1295715324

Payments from drug & device makers

$1,855in general payments, 2019–2025

Across 88 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$414
  • AbbVie$330
  • Bausch & Lomb Americas Inc.$209
  • Tarsus Pharmaceuticals, Inc.$175
  • Novartis$97
  • Rayner Intraocular Lenses Limited$95
  • plus $534 from 14 others

What the payments were for

  • Food & beverage$1,80097%
  • Education$553%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,855 in reported general payments places this provider in the 60th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$412,279
Medicare patients
1,353
Services billed
4,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine67$93,441
LumiganBimatoprost144$75,289
Cyclosporine60$36,272
MieboPerfluorohexyloctane/Pf19$22,035
RocklatanNetarsudil Mesylat/Latanoprost25$16,813
XiidraLifitegrast15$16,066
Prednisolone Acetate415$11,271
CombiganBrimonidine Tartrate/Timolol22$10,602
RhopressaNetarsudil Mesylate32$10,581
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol66$9,216
Brimonidine Tartrate108$9,171
MoxifloxacinMoxifloxacin Hcl332$8,601
Ketorolac Tromethamine407$6,815
VyzultaLatanoprostene Bunod16$6,470
Latanoprost621$5,975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$330$185,251244 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$209$44,57250 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$86$27,39457 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate$82$8,15736 claims
AlconSimbrinza$86$4,27815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Portsmouth

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →